Download PDF
Thromb Haemost 2018; 118(04): 778-790
DOI: 10.1055/s-0038-1629912
Atherosclerosis and Ischaemic Disease
Schattauer Stuttgart

Fibrinogen and Neopterin Is Associated with Future Myocardial Infarction and Total Mortality in Patients with Stable Coronary Artery Disease

Øistein Rønneberg Mjelva
1   Department of Clinical Science, University of Bergen, Bergen, Norway
2   Department of Medicine, Stavanger University Hospital, Stavanger, Norway
,
Gard F.T. Svingen
1   Department of Clinical Science, University of Bergen, Bergen, Norway
,
Eva K.R. Pedersen
1   Department of Clinical Science, University of Bergen, Bergen, Norway
,
Reinhard Seifert
3   Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
,
Jan Terje Kvaløy
4   Department of Research, Stavanger University Hospital, Stavanger, Norway
5   Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway
,
Øivind Midttun
6   Bevital AS, Bergen, Norway
,
Per M. Ueland
1   Department of Clinical Science, University of Bergen, Bergen, Norway
7   Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway
,
Jan E. Nordrehaug
1   Department of Clinical Science, University of Bergen, Bergen, Norway
8   Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
,
Ottar Nygård
1   Department of Clinical Science, University of Bergen, Bergen, Norway
3   Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
,
Dennis W.T. Nilsen
1   Department of Clinical Science, University of Bergen, Bergen, Norway
8   Department of Cardiology, Stavanger University Hospital, Stavanger, Norway
› Author Affiliations
Further Information

Publication History

09 May 2017

29 December 2017

Publication Date:
19 February 2018 (online)

   Permissions and Reprints

Abstract

Systemic fibrinogen and neopterin are related to inflammation. We investigated the prognostic utility and possible interactions of these biomarkers in stable coronary artery disease (SCAD) patients undergoing coronary angiography. We included 3,545 patients with suspected stable angina with a median follow-up of 7.3 and 10.2 years for incident acute myocardial infarction (AMI) and all-cause mortality, respectively. Prospective associations were explored by Cox regression. Potential effect modifications were investigated according to strata of fibrinogen, neopterin or high-sensitivity troponin T (hsTnT) below and above the median, as well as gender and smoking habits. During follow-up, 543 patients experienced an AMI and 769 patients died. In a multivariable model, the hazard ratios (HRs; 95% confidence interval [CI]) per 1 SD increase for fibrinogen in relation to these endpoints were 1.30 (1.20, 1.42; p < 0.001) and 1.22 (1.13, 1.31; p < 0.001), respectively. For neopterin, the HRs (95% CI) were 1.31 (1.23, 1.40; p < 0.001) and 1.24 (1.15, 1.34; p < 0.001), respectively. No significant interaction between fibrinogen and neopterin was observed. The prognostic utility of neopterin for incident AMI was improved in patients with an hsTnT above the median, for total mortality in non-smokers, and for both total mortality and AMI in females. In conclusion, both fibrinogen and neopterin were associated with future AMI and total mortality, but had low discriminatory impact. No interaction was observed between these two biomarkers. The prognostic utility of neopterin was improved in patients with hsTnT levels above the median, and in females and non-smokers.

Keywords

fibrinogen - neopterin - hsTnT - prognosis - stable coronary artery disease

Supplementary Material

 

  • References

  • 1 Bridge KI, Philippou H, Ariëns R. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112 (05) 901-908
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev 2011; 25 (06) 239-245
    CrossrefPubMedGoogle Scholar
  • 3 Espinola-Klein C, Rupprecht HJ, Bickel C. , et al; AtheroGene Investigators. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007; 195 (02) e126-e134
    CrossrefPubMedGoogle Scholar
  • 4 Coppola G, Rizzo M, Abrignani MG. , et al. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. Ital Heart J 2005; 6 (04) 315-322
    PubMedGoogle Scholar
  • 5 Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258 (09) 1183-1186
    CrossrefPubMedGoogle Scholar
  • 6 Wolberg AS. Primed to understand fibrinogen in cardiovascular disease. Arterioscler Thromb Vasc Biol 2016; 36 (01) 4-6
    CrossrefPubMedGoogle Scholar
  • 7 Vrecko K, Staedtler P, Mischak I, Maresch L, Reibnegger G. Periodontitis and concentrations of the cellular immune activation marker neopterin in saliva and urine. Clin Chim Acta 1997; 268 (1-2): 31-40
    CrossrefPubMedGoogle Scholar
  • 8 Müller TF, Vogl M, Neumann MC, Lange H, Grimm M, Müller MM. Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 1998; 276 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 9 Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA. Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?. Acute Card Care 2007; 9 (04) 197-206
    CrossrefPubMedGoogle Scholar
  • 10 Adachi T, Naruko T, Itoh A. , et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart 2007; 93 (12) 1537-1541
    PubMedGoogle Scholar
  • 11 Gieseg SP, Crone EM, Flavall EA, Amit Z. Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis. Br J Pharmacol 2008; 153 (04) 627-635
    CrossrefPubMedGoogle Scholar
  • 12 Pawashe AB, Golino P, Ambrosio G. , et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74 (01) 56-63
    CrossrefPubMedGoogle Scholar
  • 13 Ragni M, Cirillo P, Pascucci I. , et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93 (10) 1913-1918
    CrossrefPubMedGoogle Scholar
  • 14 De Rosa S, Cirillo P, Pacileo M. , et al. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol 2011; 9 (02) 188-199
    CrossrefPubMedGoogle Scholar
  • 15 Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26 (05) 319-329
    CrossrefPubMedGoogle Scholar
  • 16 Schumacher M, Halwachs G, Tatzber F. , et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997; 30 (03) 703-707
    CrossrefPubMedGoogle Scholar
  • 17 Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000; 83 (03) 346-350
    CrossrefPubMedGoogle Scholar
  • 18 Auer J, Berent R, Labetanig E, Eber B. Serum neopterin and activity of coronary artery disease. Heart Dis 2001; 3 (05) 297-301
    PubMedGoogle Scholar
  • 19 Melichar B, Gregor J, Solichová D, Lukes J, Tichý M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994; 40 (02) 338-339
    CrossrefPubMedGoogle Scholar
  • 20 Gupta S, Fredericks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997; 349 (9060): 1252-1253
    PubMedGoogle Scholar
  • 21 Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999; 83 (04) 515-518
    CrossrefPubMedGoogle Scholar
  • 22 Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000; 35 (04) 956-962
    CrossrefPubMedGoogle Scholar
  • 23 Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int J Cardiol 2006; 111 (02) 318-320
    CrossrefPubMedGoogle Scholar
  • 24 van Haelst PL, Liem A, van Boven AJ. , et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003; 92 (10) 1201-1203
    CrossrefPubMedGoogle Scholar
  • 25 Ray KK, Morrow DA, Sabatine MS. , et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115 (24) 3071-3078
    CrossrefPubMedGoogle Scholar
  • 26 Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ. , et al; SIESTA Investigators. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008; 201 (01) 176-183
    CrossrefPubMedGoogle Scholar
  • 27 Nazer B, Ray KK, Sloan S. , et al. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J 2011; 32 (11) 1390-1397
    CrossrefPubMedGoogle Scholar
  • 28 Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26 (05) 457-463
    CrossrefPubMedGoogle Scholar
  • 29 Pedersen ER, Midttun Ø, Ueland PM. , et al. Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2011; 31 (03) 698-704
    CrossrefPubMedGoogle Scholar
  • 30 Lyngbæk S, Winkel P, Gøtze JP. , et al; CLARICOR Trial Group. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol 2014; 21 (10) 1275-1284
    CrossrefPubMedGoogle Scholar
  • 31 Ebbing M, Bleie Ø, Ueland PM. , et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300 (07) 795-804
    CrossrefPubMedGoogle Scholar
  • 32 Svingen GF, Ueland PM, Pedersen EK. , et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 2013; 33 (08) 2041-2048
    CrossrefPubMedGoogle Scholar
  • 33 Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36 (03) 959-969
    CrossrefPubMedGoogle Scholar
  • 34 Sulo G, Igland J, Vollset SE. , et al. Cardiovascular disease and diabetes mellitus in Norway during 1994 -2009; CVDNOR - nationwide research project. Nor Epidemiol 2013; 23 (01) 101-107 (DOI: http://dx.doi.org/10.5324/nje.v23i1.1609)
    PubMedGoogle Scholar
  • 35 Midttun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009; 23 (09) 1371-1379
    CrossrefPubMedGoogle Scholar
  • 36 Jarolim P. High sensitivity cardiac troponin assays in the clinical laboratories. Clin Chem Lab Med 2015; 53 (05) 635-652
    PubMedGoogle Scholar
  • 37 Team RCR. A Language and Environment for Statistical Computing. 3.3.1 ed. Vienna, Austria: R Foundation for Statistical Computing; 2016
    Google Scholar
  • 38 Tabakci MM, Gerin F, Sunbul M. , et al. Relation of plasma fibrinogen level with the presence, severity, and complexity of coronary artery disease. Clin Appl Thromb Hemost 2017; 23 (06) 638-644
    CrossrefPubMedGoogle Scholar
  • 39 Sinning JM, Bickel C, Messow CM. , et al; AtheroGene Investigators. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006; 27 (24) 2962-2968
    CrossrefPubMedGoogle Scholar
  • 40 Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2009; 55 (06) 1135-1146
    CrossrefPubMedGoogle Scholar
  • 41 Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41 (02) 402-417
    CrossrefPubMedGoogle Scholar
  • 42 Diamondstone LS, Tollerud DJ, Fuchs D. , et al. Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population. J Clin Immunol 1994; 14 (06) 368-374
    CrossrefPubMedGoogle Scholar
  • 43 Woodward M, Lowe GD, Rumley A. , et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97 (04) 785-797
    CrossrefPubMedGoogle Scholar
  • 44 Schennach H, Murr C, Gächter E, Mayersbach P, Schönitzer D, Fuchs D. Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem 2002; 48 (04) 643-645
    CrossrefPubMedGoogle Scholar
  • 45 Djordjevic VB, Stojanovic I, Cosic V. , et al. Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-alpha levels in patients with ischemic heart disease. Clin Chem Lab Med 2008; 46 (08) 1149-1155
    PubMedGoogle Scholar
  • 46 Midttun O, Townsend MK, Nygård O. , et al. Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. J Nutr 2014; 144 (05) 784-790
    CrossrefPubMedGoogle Scholar